Opko Health Inc.  

(Public, NYSE:OPK)   Watch this stock  
Find more results for OPK
+0.07 (0.80%)
Jul 10 - Close
NYSE real-time data - Disclaimer
Currency in USD
Range 8.59 - 8.99
52 week 7.14 - 12.95
Open 8.64
Vol / Avg. 2.59M/2.65M
Mkt cap 3.63B
P/E     -
Div/yield     -
EPS -0.33
Shares 413.75M
Beta 1.09
Inst. own 17%
Aug 4, 2014
Q2 2014 Opko Health Inc. Earnings Release (Estimated) Add to calendar
Jun 24, 2014
OPKO Health Inc Hold Conference Call to Discuss Six Month Data from Phase 2 hGH-CTP Trial
Jun 3, 2014
Opko Health Inc. at Jefferies Global Healthcare Conference
May 9, 2014
Q1 2014 Opko Health Inc. Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '14) 2013
Net profit margin -193.21% -109.70%
Operating margin -135.93% -82.49%
EBITD margin - -66.71%
Return on average assets -12.57% -12.60%
Return on average equity -20.88% -21.75%
Employees 549 -
CDP Score - -


MIAMI, FL 33137
United States - Map
+1-305-5754138 (Phone)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


OPKO Health, Inc. (OPKO) is a multi-national biopharmaceutical and diagnostics company. OPKO is developing a range of solutions to diagnose, treat and prevent various conditions, including molecular diagnostics tests, laboratory developed tests (LTDs), point-of-care tests and pharmaceuticals and vaccines. The Company operates in two segments: pharmaceutical and diagnostics. The pharmaceutical segment consists of two operating segments: pharmaceutical research and development segment which is focused on the research and development of pharmaceutical products and vaccines, and the pharmaceutical operations it acquired in Chile, Mexico, Israel, and Spain through acquisitions in those countries. Effective May 28, 2014, OPKO Health Inc acquired Inspiro Medical Ltd, a Misgav-based manufacturer and wholesaler of pharmaceuticals.

Officers and directors

Phillip Frost M.D. Chairman of the Board, Chief Executive Officer
Age: 77
Bio & Compensation  - Reuters
Jane H. Hsiao Ph.D. Vice Chairman of the Board, Chief Technical Officer
Age: 66
Bio & Compensation  - Reuters
Adam E. Logal Chief Financial Officer, Senior Vice President
Age: 35
Bio & Compensation  - Reuters
Steven D. Rubin Esq. Executive Vice President - Administration, Director
Age: 53
Bio & Compensation  - Reuters
Thomas E. Beier Director
Age: 68
Bio & Compensation  - Reuters
Robert A. Baron Independent Director
Age: 74
Bio & Compensation  - Reuters
Dmitry Iurevich Kolosov Independent Director
Age: 34
Bio & Compensation  - Reuters
Richard A. Lerner M.D. Independent Director
Age: 75
Bio & Compensation  - Reuters
John A. Paganelli Independent Director
Age: 79
Bio & Compensation  - Reuters